Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, Beijing, People's Republic of China.
Stem Cells. 2018 Mar;36(3):446-457. doi: 10.1002/stem.2760. Epub 2018 Jan 10.
During bone marrow transplantation, hematopoietic stem and progenitor cells (HSPCs) respond to signals from the hematopoietic microenvironment by coordinately activating molecular pathways through Rho GTPases, including Rac. We have previously shown that deletion of Vav1, a hematopoietic-specific activator of Rac, compromises engraftment of transplanted adult HSPCs without affecting steady-state hematopoiesis in adult animals. Here, we show that Vav1 fetal HSPCs can appropriately seed hematopoietic tissues during ontogeny but cannot engraft into lethally irradiated recipients. We demonstrate that the engraftment defect of Vav1 HSPCs is abrogated in the absence of irradiation and demonstrate that Vav1 is critical for the response of HSPCs to the proinflammatory cytokine interleukin-11 (IL-11) that is upregulated in the marrow of irradiated recipients. Vav1 HSPCs display abnormal proliferative responses to IL-11 in vitro and dysregulated activation of pathways critical to engraftment of HSPCs. The engraftment of Vav1 HSPCs can be partially rescued in irradiated recipients treated with an anti-IL-11 antibody. These data suggest that HSPCs may respond to different functional demands by selective usage of the IL-11-Vav-Rac pathway, contextualizing further the recent view that HSPCs capable of reconstituting the blood system following transplantation might be distinct from those supporting hematopoiesis during homeostatic conditions. Stem Cells 2018; 36:446-457.
在骨髓移植中,造血干祖细胞(HSPCs)通过协调激活 Rho GTPases 中的分子途径(包括 Rac)来响应造血微环境的信号。我们之前已经表明,删除造血特异性 Rac 激活剂 Vav1 会损害移植的成年 HSPC 的植入,而不会影响成年动物的稳态造血。在这里,我们表明 Vav1 胎儿 HSPCs 可以在胚胎发生期间适当地定殖造血组织,但不能植入致死性照射的受体中。我们证明,在没有照射的情况下,Vav1 HSPCs 的植入缺陷被消除,并证明 Vav1 对于 HSPC 对炎性细胞因子白细胞介素 11(IL-11)的反应至关重要,白细胞介素 11 在照射受体的骨髓中上调。Vav1 HSPCs 在体外对白细胞介素 11 显示出异常的增殖反应,并失调地激活了对 HSPC 植入至关重要的途径。用抗白细胞介素 11 抗体治疗照射受体可以部分挽救 Vav1 HSPCs 的植入。这些数据表明,HSPCs 可能通过选择性使用白细胞介素 11-Vav-Rac 途径来响应不同的功能需求,进一步说明最近的观点,即能够在移植后重建血液系统的 HSPCs 可能与在稳态条件下支持造血的 HSPCs 不同。干细胞 2018;36:446-457。